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Upper gastrointestinal bleeding (UGIB) is a common Emergency Centre presentation with a high mortality (5–30%). Despite theoretical beneﬁts, tranexamic acid is not
widely used for this condition. Tranexamic acid is widely available in the developing world and is on the World Health Organisation’s essential medicines list. This
review considers the following three-part question: ‘‘In adult patients with upper gastrointestinal bleeding, does tranexamic acid decrease mortality? A systematic review
of the literature was performed (1900–2012). Databases searched included: MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, National Research
Register, NIHR CRN portfolio, and http://ClinicalTrials.gov/. Grey literature databases searched included: Open Grey, Worldcat.org and Google Scholar. The con-
clusion of this review is that in adult patients with upper gastrointestinal bleeding, the administration of tranexamic acid may lead to a signiﬁcant decrease in mortality.Le saignement gastro-intestinal supe´rieur (SGIS) constitue une affection courante dans les centres d’urgence entraıˆnant un taux de mortalite´ e´leve´ (5–30%). Malgre´ les
avantages the´oriques, l’acide tranexamique n’est pas largement utilise´ pour traiter cette affection. L’acide tranexamique est largement disponible dans le monde en
de´veloppement et ﬁgure sur la liste des me´dicaments essentiels de l’Organisation mondiale de la Sante´. Cette e´tude se penche sur la question suivante a` trois volets:
« Chez les patients adultes souffrant de saignements gastro-intestinaux supe´rieurs, l’acide tranexamique fait-il diminuer la mortalite´ ? » Une e´tude syste´matique de
la litte´rature a e´te´ re´alise´e (1900–2012). Les bases de donne´es consulte´es ont notamment e´te´ les suivantes: MEDLINE, EMBASE, Cochrane Central Register of
Controlled Trials, National Research Register, NIHR CRN Portfolio et http://ClinicalTrials.gov/. Les bases de donne´es consulte´es dans la documentation non ofﬁcielle
(litte´rature « grise ») ont notamment e´te´ les suivantes: Open Grey, Worldcat.org et Google Scholar. La conclusion de cette e´tude est que chez les patients adultes
souffrant de saignements gastro-intestinaux supe´rieurs, l’administration d’acide tranexamique peut conduire a` une diminution signiﬁcative de la mortalite´.African relevance
 Tranexamic acid is widely available throughout Africa.
 Tranexamic acid is likely to reduce mortality in upper
gastrointestinal bleeding.
 An initial dose of 1 g IV should be given followed by 1 g
TDS/QDS.
Introduction
Upper gastrointestinal bleed (UGIB) is a relatively common
medical presentation worldwide, accounting for a signiﬁcant
number of emergency centre (EC) visits.1 Despite having ahigh mortality (5–30%2), evidence-based medical treatment
options for this condition remain sparse.
In the past thirty years, medical treatment for UGIB has
centred on proton pump inhibitor therapy and, in selected cas-
es, somatostatin analogues. Recent Cochrane reviews do not
support the routine use of either of these therapies.3,4
Tranexamic acid (TXA) is a widely available antiﬁbrinolyt-
ic medication that has been used clinically in various settings,
including resource poor environments, since its development in
the 1960s. It is most commonly used in the context of both sev-
ere bleeding and predicted severe bleeding (e.g., surgical inter-
vention).5 It is currently not commonly used in the
management of UGIB.2,6
UGIB is deﬁned as bleeding originating from a source
proximal to the ligament of Treitz: the duodenojejunal junc-
tion. Causes of major UGIB bleeding can be found in Table 1.
The challenge of obtaining rapid haemostasis in those with
UGIB is multifactorial. Patient related factors include propen-
sity to bleed without clot formation (e.g., those on warfarin)
and those with inherent clotting abnormalities (e.g., alcohol
related liver disease).
Table 1 Causes of major UGIB.
Peptic ulcer disease (30–50%)6
Oesophageal and gastric varices
Haemorrhagic gastritis
Oesophagitis
Duodenitis
Mallory-Weiss tear
Angiodysplasia
Upper gastrointestinal malignancy
Anastomotic ulcers (after PUD surgery or bariatric surgery)
Dieulafoy lesion
Note: PUD= peptic ulcer disease.
Adapted from: Ref. [1].
Papers idenﬁed from 
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Figure 1 Flow diagram of process of systematic literature
search.
86 T. NutbeamThe gastric and duodenal environment is hostile to clot for-
mation. Clot formation is impaired by:
– Direct effect of the acidic environment impairing platelet
aggregation and clot formation.7
– Acceleration of clot lysis by gastric juice. This ﬁbrinolytic
effect is likely to be mediated both by pepsin and other
unknown acid dependent proteases.8,9
– Gastrointestinal mobility during haemorrhage.10
– Marked vascularity with the absence of autoregulation of
local blood ﬂow.8
TXA is a plasminogen inhibitor. Plasminogen is a precursor
to plasmin, a key enzyme in ﬁbrinolysis. In addition, TXA has
a direct effect on reducing the ﬁbrinolytic activity of pepsin
independent of pH. It is postulated that TXA also has a
signiﬁcant effect on other proteases that cause clot
destruction.8,9,11–15
More recently, TXA has been identiﬁed as having anti-in-
ﬂammatory effects. This is achieved by binding to cells
involved in the inﬂammation process including macrophages,
neutrophils, etc., as well as inhibiting the pro-inﬂammatory
effects of plasminogen.16
Objective
The objective of this review is demonstrated using a three-part
question: In [adult patients presenting as an emergency with
upper gastrointestinal bleeding] does [tranexamic acid]
decrease [mortality]?
Various surrogate markers are used throughout this lit-
erature base. Mortality is a deﬁnitive patient centred outcome,
which has clear diagnostic criteria and is not subject to the bias
of other measures such as rebleeding or transfusion
requirements.17,18
Literature search methodology
A literature search was conducted for all journal article types,
including but not limited to: basic science, in vitro studies,
guidelines, clinical and preclinical trials of all designs, (system-
atic) reviews, and meta-analyses on the use of TXA in UGIB.
Search dates were from January 1900 through October 2012.
Various combinations of searches were carried out. Upper gas-
trointestinal bleeding is subject to varied terminology withinthe literature. Narrower search strategies attempting to identi-
fy this speciﬁc bleeding subset were deemed unsuccessful and
the search terms were ultimately rejected. The ﬁnal search
terms were Tranexamic Acid AND (bleed$ or haemorrhage).
By starting with a wide comprehensive search strategy, the
effect of synonyms, related terms, and variant spellings was
minimised whilst simultaneously decreasing the likelihood of
missing relevant publications. This search strategy was adapt-
ed and applied to MEDLINE (using the PubMed Interface),
EMBASE (via NHS Athens), Cochrane Central Register of
Controlled Trials, National Research Register (NRR),
NIHR CRN portfolio, and http://ClinicalTrials.gov/. Grey lit-
erature databases were also searched and included Open Grey,
Worldcat.org, and Google Scholar. All searches were conﬁned
to the English language. A manual review of abstracts when
available, and otherwise the full texts, was performed with
items relevant to the objective included for second review.
On second review, full texts were reviewed and those relevant
to the objective included. A ﬁnal review of reference lists from
relevant articles was carried out and articles relevant to the
objective were also included for ﬁnal review (Fig. 1).
Review of the literature
Lab and animal studies
A small number of in vitro and animal studies report the var-
ious stages of gastric clot formation, subsequent ﬁbrinolysis
and the effect TXA has upon these processes.8,9,11–15 All of
the studies report a relationship between TXA and improved
clot formation and maintenance.
Case series
Two case series’ with 98 and 159 consecutive patients were all
treated with TXA and conventional therapy.19,20 The authors
report a lower than expected mortality rate of 4.1% and
4.5%, respectively, and conclude that their treatment protocol
was successful.
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Sabovic et al. report a series of 20 consecutive renal dialysis
patients with a total of 36 episodes of UGIB.21 Physicians
chose whether to administer TXA or not (a clear source of
bias); additionally no blinding occurred and no placebo was
used. The authors reported a statistically signiﬁcant
(p< 0.05) reduction in: early rebleeding, early and late
rebleeding, repeated endoscopic procedure, and the number
of blood transfusions required.Randomised controlled trials
Seven randomised controlled trials (RCT) were identiﬁed that
were relevant to the study question.
1. Cormack et al. (1973): Tranexamic acid in upper gastroin-
testinal haemorrhage
The ﬁrst of these trials was published in 1973.22 Cormack
et al. report a RCT of 150 consecutive patients carried out
between 1969 and 1971 at a single centre (UK). They include
all patients presenting with frank haematemesis or melaena
but lack clarity in their exclusion criteria: ‘‘those with condi-
tions known to be fatal’’. The authors do not describe their
methods of randomisation or the extent of their blinding
(described as double blind). The intervention was oral TXA
1.5 g 8hrly or placebo tablets. A composite endpoint was used:
‘‘treatment failure’’ which included death, need for surgery,
and rebleeding. Seventy-six patients received TXA and 74
placebo. The groups were well matched in terms of age, sex,
and severity of symptoms. Intention to treat analysis was car-
ried out for primary endpoint. When the composite primary
endpoint of treatment failure was considered, a non-signiﬁcant
difference was reported: 15 patients failed treatment in the
TXA group and 20 in the placebo group. The authors go on
to describe an unplanned subgroup analysis (excluding
patients with hiatus hernia or oesophageal varices – a barium
meal was carried out on survivors) in which they report a sta-
tistically signiﬁcant (p< 0.05) outcome between the groups in
favour of TXA in relation to treatment failure. This is a clear
example of survivor bias.
The authors recruit a further ten patients at the end of the
study to test oral absorption of TXA. They report that it is
well absorbed via the oral route despite concurrent UGIB.
Author’s ﬁnal discussion recommends TXA for bleeding
distal to the gastroesophageal junction – to be conﬁrmed by
gastroscopy prior to initiation of treatment. The authors
report that the trial was industry sponsored.
2. Engqvist et al. (1979): Tranexamic acid in massive haemor-
rhage from the upper gastrointestinal tract: a double blind
study
This study was published in 1979, four years after study’s
completion.23 This single-centre study (Stockholm) of intensive
care patients was conducted over 15 months: 1974–5. Patients
required a history of haematemesis and/or melaena with
deﬁned measurable signs of circulatory ‘embarrassment’ to
be included in the trial. Patients were excluded with either a
history of thromboembolism or renal disease. It is not clearif consecutive patients were recruited or assessed for eligibility.
Restricted randomisation was used to ensure equal distribu-
tion of males and females. Patients received either TXA in
intensive care at 1 g 4hrly IV (maximum three days) and then
on ward 1.5 g 6hrly (maximum four days) or an equivalent IV
or oral placebo. Primary or secondary endpoints are not
deﬁned in the methodology.
Of 204 patients entering the study, many (55) were excluded
on the basis of only minor bleeding or having not received
therapy according to the protocol. Intention to treat analysis
was not performed. Of patients analysed, 76 received TXA
and 73 placebo. The investigators found a lower rate of contin-
ued bleeding, operations, and deaths in the TXA group; none
of these achieved statistical signiﬁcance.
3. Biggs et al. (1976): Tranexamic acid and upper gastroin-
testinal haemorrhage – a double blind trial
This single centre Australian study recruited consecutive
patients presenting to the EC with conﬁrmed symptoms of
UGIB – a witnessed episode or positive gastric aspirate.24
Patients not admitted to the hospital, those who were preg-
nant, had chronic renal impairment, vascular surgery, or a
thromboembolic event in the preceding 12 months were
excluded. Patients were randomised to receive 1 g IV and 1 g
PO 8hrly for 48 h followed by 1 g PO 8hrly for a further
72 h or an equivalent placebo. The trial was conducted in a
double blind fashion. The authors do not name their primary
endpoints but recorded transfusion requirements, requirement
for surgery and mortality. Two hundred patients (unpowered)
were recruited; 103 received treatment and 97 placebo. The
authors found no statistical signiﬁcance in transfusion require-
ments or mortality (two died in TXA group, four in placebo
group). They did ﬁnd statistically less operative intervention
required in the treatment group (seven in TXA group, 21 in
placebo group). This trial was industry sponsored.
4. Berqvist et al. (1980): Local inhibition of the ﬁbrinolytic sys-
tem in patients with massive upper gastrointestinal
hemorrhage.25
This unpowered, single centre trial recruited 50 patients
with haematemesis and/or melaena that had signs of circulato-
ry compromise (undeﬁned). Patients were randomised to
receive NG placebo or TXA 2 g 4hrly for 48 h. The trial was
conducted in a double blind manner. Following exclusions
on the basis of incorrectly enrolled patients and concurrent
therapies, 22 patients remained in the placebo group and 21
in the treated group; intention to treat analysis was not per-
formed. The trial found no difference in operative frequency
but a large difference in mortality: placebo 22.7%, and TXA
12.3%, however p-values were not reported.
5. Barer et al. (1983): Cimetidine and tranexamic acid in the
treatment of acute upper-gastrointestinal-tract bleeding.26
This study was conducted across two hospitals in the UK
from January 1980–1982. All patients admitted via EC with
a primary diagnosis of haematemesis and/or melaena were
considered for eligibility. Patients with bleeding requiring
immediate operative intervention, other ‘‘serious medical con-
ditions’’ that primarily affected management, and in those
88 T. Nutbeamwhere the bleeding was not considered serious were excluded.
Patients were randomised in blocks of six to receive a treat-
ment pack containing cimetidine (40 g IV 6hrly for 48 h, fol-
lowed by 400 mg PO 6hrly for 5 days), TXA (1 g IV 6hrly
for 48 h followed by 1 g PO 6hrly for 5 days) or an identically
appearing placebo to the same schedule. The study was pow-
ered with an 85% chance of detecting a signiﬁcant
(p< 0.05) halving of either rebleeding or death in either group
(750 patients). Seven hundred and seventy-ﬁve patients were
recruited across the three groups (achieved power). On inten-
tion to treat analysis, no difference was found in regard to
rebleeding and operation rates. However, both TXA and cime-
tidine achieved a statistically signiﬁcant decrease in mortality
with an actual risk reduction (ARR) of 7.2% and 5.7% respec-
tively when compared to placebo. For TXA, this is a relative
risk reduction (RRR) of >50%.
6. Von Holstein et al. (1987): Tranexamic acid as an aid
to reducing blood transfusion requirements in gastric and
duodenal bleeding.27
This single centre study recruited all patients presenting
with suspected UGIB to a Swedish hospital. Patients were
excluded if they had thromboembolic disease, bleeding or
coagulation defects, were taking anticoagulants, or were preg-
nant. Patients were randomised in blocks of ten to receive
TXA or placebo IV 1 g every 4hrly for 3 days followed by
1.5 g PO 6hrly for a further 3 days. After allocation, patients
were examined endoscopically. Those with evidence of cancer,
an oesophageal source of bleeding, or no clear source of bleed-
ing were excluded. Additionally, patients with evidence of
renal failure were also excluded. Intention to treat was not per-
formed. Blood was transfused to a pre-established guideline
but indications for surgery were softer. The study was powered
for a primary outcome of ‘‘blood loss’’ (150 patients). One
hundred and ﬁfty-four of a total of 328 recruited patients were
included for ﬁnal analysis (achieved power). The trial found
statistically signiﬁcant differences for blood transfusions (2.2
vs 3.2 units p= 0.018) and operation rates (p= 0.010).
More patients in the placebo group rebled (19 vs 10) and died
(4 vs 2), however, neither of these achieved statistical
signiﬁcance.Cormack 1973
Biggs 1976
Engqvist 1979
Bergqvist 1980
Barer 1983
von Holstein 1987
Hawkey 2001
Total
Events
3
2
11
3
16
2
4
41
Total
76
103
102
25
256
164
103
829
Events
3
4
12
5
35
4
5
68
To
7
9
10
2
26
16
10
82
TXA Placebo
Figure 2 Forest plot of randomised controlled t7. Hawkey et al. (2001): Drug Treatments in upper gastroin-
testinal bleeding: value of endoscopic ﬁndings as surrogate
end points.18
This trial takes a different approach to those previously dis-
cussed. The ﬁrst of two aims was to develop a measure to
reﬂect bleeding severity and subsequent clinically important
end points. The second was to assess the effect of oral medica-
tions (TXA and a PPI) on this end point. Four hundred and
fourteen (powered to 400) consecutive patients with suspected
UGIB were enrolled in this two-centre study (UK). Those
requiring immediate surgery, with conditions making active
treatment inappropriate (e.g., malignancy), pregnancy, lacta-
tion, active thromboembolism, coagulopathy, renal failure,
or on phenytoin were excluded. Patients were block ran-
domised to receive TXA (PO 2 g followed by 1 g QDS),
Lansoprazole (60 mg PO followed by 30 mg QDS), both
regimes combined, or placebo. A double dummy technique
was used to maintain blinding. Patients were endoscoped with
adrenaline therapy and given an endoscopic assessment score.
Multiple clinical outcome analysis and complex multi-regres-
sion were used to draw conclusions. The authors conclude that
the presence of blood in the stomach reﬂected subsequent clin-
ical risk and therefore TXA, Lansoprazole, and a combination
of the two without synergism reduced this blood.
Reviews and systematic reviews
A number of reviews of varying quality were identiﬁed in the
literature search. Seven reviewed a range of drug treatments
for UGIB6,28–35, two papers review the efﬁcacy of TXA/an-
tiﬁbrinolytics in a variety of clinical settings31,34) and one
focused on TXA in UGIB.36 The majority of reviews presented
the use of TXA in UGIB in a positive context, with the excep-
tion of those carried out by North American authors.6,28,30,35
Meta-analyses
The literature search identiﬁed two meta-analyses, the ﬁrst
performed by Henry and O’Connell in 1989.37 After an
appropriate literature search, this well thought out studytal
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Table 2 Summary of randomised controlled trials.
Author year Centre Patients Exclusions Intervention Outcome Included Results Side eﬀects
Cormack
et al. (1973)
Single, UK Admitted
patients: all
haematemesis or
melaena
Unclear: ‘‘Conditions
known to be fatal’’
Oral TXA, 1.5 g
8hrly
Composite: death,
need for surgery,
rebleeding
150 No diﬀerence for
primary endpoints
1 Patient had nausea
and vomiting (TXA)
Engvist
et al. (1979)
Single, Sweden ICU patients
with
haematemesis
and/or melaena
with ‘‘circulatory
embarrassment’’
History of thrombo-
embolism or deﬁned
renal failure
IV TXA, 1 g
4hrly for 3 days,
then PO 1.5 g
QDS for 4 days
Unclear but included
death, need for surgery
and rebleeding
149 Trend towards less
deaths, need for
surgery and rebleeding
in intervention group
(non-signiﬁcant)
4 Thrombo-embolic
episodes in TXA group,
2 in placebo
Biggs et al.
(1976)
Single,
Australia
ED patients:
witnessed
haematemesis or
positive gastric
aspirate
Not admitted,
pregnant, CRF,
history of thrombo-
embolism, vascular
surgery
Oral and IV
TXA, 1 g 8hrly
for 2 days, then
PO 1 g 8hrly for
3 days
Unclear but included
death, need for surgery
and transfusion
requirements
200 No diﬀerence in
mortality, transfusion
requirements. Less
operative intervention
in intervention group
(statistically
signiﬁcant)
None major. Minor
similar between groups.
Bergqvist
et al. (1980)
Single, Sweden Unclear
population: with
haematemesis
and/or melaena
with undeﬁned
shock
Not stated NG TXA, 2 g
4hrly for 2 days
Requirement for and
day of operation,
death and day of death
43 Decrease in mortality
in intervention group
(p-value not reported)
Not discussed
Barer et al.
(1983)
Two, UK Admitted with
primary
diagnosis of
haematemesis or
melaena
Immediate operative
intervention, ‘‘serious
medical conditions’’,
not serious bleeding
IV TXA, 1 g
6hrly for 2 days,
then PO 1 g QDS
for 5 days
Death, need for
surgery and rebleeding
775 Statistically signiﬁcant
decrease in mortality
1 Thrombo-embolic
episode in patient with
polycythemia (TXA
group)
Von
Holstein
et al. (1987)
Single, Sweden Admitted
patients with
suspicion of
UGIB
Thrombo-embolic
disease, bleeding or
coagulation defect or
on anticoagulants
IV TXA, 1 g
4hrly for 3 days,
then PO 1 g QDS
for 3 days
Transfusion
requirements, need for
surgery, rebleeding
and death
154 Statistically signiﬁcant
decrease in transfusion
requirement and need
for surgery
2 Episodes of thrombo-
phlebitis and 1 thrombo-
embolic episode (TXA
group)
Hawkey
et al. (2001)
Two, UK Admitted
patients with
suspicion of
UGIB
Immediate operative
intervention, pregnant,
lactating, deﬁned renal
failure, coagulopathic,
on phenytoin
PO TXA 2 g
followed by 1 g
QDS
Blood in stomach as
predictor of clinical
risk
414 Statistically signiﬁcant
decrease in blood in
the stomach for TXA
No diﬀerence between
groups
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90 T. Nutbeamidentiﬁed the ﬁrst six RCTs discussed above as suitable for
inclusion.22,23,25–27 They identiﬁed and overcame the failure
of some of the authors to carry out intention to treat analysis
by contacting the authors directly and successfully obtaining
the data of excluded patients in all but one trial. The authors
combined 1267 patients for analysis. Unable to accurately
assess the heterogeneity of the data, the authors carried out
a method of Peto and method of DerSimonian and Laird
analysis of outcomes. Using both methods they found a highly
statistically signiﬁcant reduction in mortality (p= 0.01 and
0.02) with an estimated effect of a 40% decrease in mortality.
Data for rebleeding and need for operative intervention were
more heterogenous as would be expected for a ‘softer’ outcome
more prone to physician bias, but achieved an estimated effect
of a 20–30% decrease in rebleeding and a 30–40% reduction in
operation rate. The authors appropriately discussed the
various bias this meta-analysis may be subject to and correctly
identiﬁed their inability to account for publication bias.
Gluud et al. took a non-narrative approach to their system-
atic review and meta-analysis which included all seven of the
RCTs discussed above.38 They performed a ‘‘worse case sce-
nario’’ statistical analysis and found potentially no difference
in mortality between intervention and placebo. They did not
use the additional data available from Henry’s meta-analysis
in their calculations. The authors concluded that TXA may
reduce mortality and had a limited side effect proﬁle (Fig. 2).
Despite this, they could not recommend its use until more evi-
dence was available. This review formed the basis of the
author’s subsequent Cochrane review.39
Discussion
Principal ﬁndings
The principal ﬁndings for the RCTs are summarised in
Table 2. In short:
– The laboratory and animal based studies present a strong
experimental base for beneﬁt from TXA.
– The two case studies and single cohort study reveal the
potential beneﬁt of TXA administration in humans.
– A majority of the RCTs show a statistically signiﬁcant ben-
eﬁt in at least one of their outcomes (Table 3).
– None of the RCTs or meta-analyses showed evidence of
harm, however, they were not powered to do this.
– Both meta-analyses provide convincing evidence of a
decrease in a solid patient centred outcome, namely, a
40% decrease in mortality.Table 3 Summary of outcomes from randomised controlled trials.
Author Mortality Rebleeding Tr
Cormack et al. No diﬀerence No diﬀerence NA
Engvist et al. Trend decrease Trend decrease NA
Biggs et al. No diﬀerence NA No
Bergqvist et al. Decrease NA NA
Barer et al. Decrease No diﬀerence No
Von Holstein et al. No diﬀerence Trend decrease De
Hawkey et al. No diﬀerence No diﬀerence NoStrengths and weaknesses
The RCTs suffer from a number of common failings that limit
their ability to unequivocally answer the clinical question.
Common strengths and weaknesses of the RCTs are
summarised in Table 4.
The quality of trial designs shows improvement over time.
A general increase in quality of trials over a similar time period
has been supported by an increasing focus on evidence-based
medicine, an increased awareness of trial design, and the
production of respected guidelines.40
A common problem across the literature is the use of ‘‘soft’’
endpoints. Unless blood transfusions and operative interven-
tions are initiated by comprehensive predeﬁned indications
there is a signiﬁcant potential for physician- introduced bias.
Henry’s meta-analysis identiﬁed heterogeneity in the operative
requirement outcome.37 The use of ‘‘harder’’ endpoints such as
in-hospital mortality though ideal, in the context of UGIB,
requires recruitment of a larger sample size.External validity and applicability
Though small differences in deﬁnitions exist between external
validity and applicability, the concept of ‘‘generalisability’’
encompasses both.
Many similarities exist between the personnel used in the
trials and our target patients. Signiﬁcant improvements in
the outcome of patients with UGIB have not occurred in the
last 30 years.28 Wide inclusion criteria and few exclusion crite-
ria, though occasionally poorly described, further enhance this
evidence base’s external validity. The most signiﬁcant threats
to these trials’ external validity are the questions over their
internal validity.
Validity in a resource poor environment
The aetiology ofUGIB is similar in European and resource poor
populations. TXA is a cheap, readily available drug, widely used
in resource poor areas. TXA is easily prepared and administered
intravenously, without the need for intensive or specialist
monitoring. The HALT-IT trial is currently recruiting patients
in a resource poor and developed world setting. This multi-cen-
tre pragmatic, randomised, double blind, placebo-controlled tri-
al aims to recruit 8,000 patients with signiﬁcant lower and upper
gastrointestinal bleeding. The pragmatic nature of this trial and
the potential for sub-group analysis could ‘prove’ validity in the
resource poor environment.ansfusion Operation Other
No diﬀerence NA
Trend decrease NA
diﬀerence Decrease NA
No diﬀerence NA
diﬀerence No diﬀerence NA
crease Decrease NA
diﬀerence No diﬀerence Decreased blood in stomach
Table 4 Summary of strengths and weaknesses of randomised controlled trials.
Author Population selection Consecutive
patients
Endpoints Powered Randomisation
type
Double blinding Intention
to treat
Industry
sponsored
Cormack et al. Unclear exclusions Yes Composite No Not described Not described Yes Yes
Engvist et al. Unclear inclusions Unclear Unclear No Block Not described No Not stated
Biggs et al. Clear Yes Unclear No Not described Not described Yes Yes
Bergqvist et al. Unclear inclusions
and exclusions
Unclear Clear No Not described Not described No Not stated
Barer et al. Clear Yes Clear Yes Block Partially described Yes Yes
Von Holstein et al. Clear Yes Clear Yes Block Partially described No Yes
Hawkey et al. Clear Yes Determined Yes Block Partially described No Yes
Effect of tranexamic acid on upper gastrointestinal bleeding 91Conclusion
It is likely that in adult patients with upper gastrointestinal
bleeding, the administration of tranexamic acid decreases
mortality. The HALT-IT trial should deﬁnitively answer this
question in the near future.
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